In our studies, we show that lenalidomide or pomalidomide could effectively target the c-Myc/IRF4 axis, and that once that axis is compromised, MM cells can no longer be rescued from growth inhibition (Figure 4). The gene discussed is MYC; the disease is Miyoshi myopathy.